GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis

American Journal of Pathology

Volumn 174, Issue 4, 2009, Pages 1544-1552

  Amann, Thomas ^a   Maegdefrau, Ulrike ^a   Hartmann, Arndt ^c   Agaimy, Abbas ^c   Marienhagen, Jörg ^a   Weiss, Thomas S ^a,b   Stoeltzing, Oliver ^a   Warnecke, Christina ^c   Schölmerich, Jürgen ^a   Oefner, Peter J ^a   Kreutz, Marina ^a   Bosserhoff, Anja K ^a   Hellerbrand, Claus ^a,b  

^a Department of Internal Medicine I ^*  (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KI 67 ANTIGEN; LACTIC ACID; MESSENGER RNA; SMALL INTERFERING RNA; HIF1A PROTEIN, HUMAN; SLC2A1 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER STAGING; CARCINOGENESIS; CELL DIFFERENTIATION; CELL MIGRATION; FEMALE; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LIVER CELL; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR GROWTH; BIOSYNTHESIS; CELL HYPOXIA; CELL MOTION; CELL PROLIFERATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; IMMUNOHISTOCHEMISTRY; LIVER TUMOR; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL HYPOXIA; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE TRANSPORTER TYPE 1; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TISSUE ARRAY ANALYSIS; TRANSFECTION;

EID: 65349095566     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2009.080596     Document Type: Article

References (38)

1. El-Serag HB: Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004, 127:S27-S34
2. Farazi PA, DePinho RA: Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006, 6:674-687
3. Bruix J, Boix L, Sala M, Llovet JM: Focus on hepatocellular carcinoma. Cancer Cell 2004, 5:215-219
4. Kim JW, Dang CV: Cancer's molecular sweet tooth and the Warburg effect. Cancer Res 2006, 66:8927-8930
5. Brahimi-Horn MC, Chiche J, Pouyssegur J: Hypoxia signalling controls metabolic demand. Curr Opin Cell Biol 2007, 19:223-229
6. Hugo-Wissemann D, Anundi I, Lauchart W, Viebahn R, de Groot H: Differences in glycolytic capacity and hypoxia tolerance between hepatoma cells and hepatocytes. Hepatology 1991, 13:297-303
7. Kong YH, Han CJ, Lee SD, Sohn WS, Kim MJ, Ki SS, Kim J, Jeong SH, Kim YC, Lee JO, Cheon GJ, Choi CW, Lim SM: [Positron emission tomography with fluorine-18-fluorodeoxyglucose is useful for predicting the prognosis of patients with hepatocellular carcinoma]. Korean J Hepatol 2004, 10:279-287
8. Khan MA, Combs CS, Brunt EM, Lowe VJ, Wolverson MK, Solomon H, Collins BT, Di Bisceglie AM: Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol 2000, 32:792-797
9. Airley RE, Mobasheri A: Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics. Chemotherapy 2007, 53:233-256
10. Medina RA, Owen GI: Glucose transporters: expression, regulation and cancer. Biol Res 2002, 35:9-26
11. Cooper R, Sarioglu S, Sokmen S, Fuzun M, Kupelioglu A, Valentine H, Gorken IB, Airley R, West C: Glucose transporter-1 (GLUT-1): a potential marker of prognosis in rectal carcinoma? Br J Cancer 2003, 89:870-876
12. Oliver RJ, Woodwards RT, Sloan P, Thakker NS, Stratford IJ, Airley RE: Prognostic value of facilitative glucose transporter Glut-1 in oral squamous cell carcinomas treated by surgical resection; results of EORTC Translational Research Fund studies. Eur J Cancer 2004, 40:503-507
13. Yamamoto T, Seino Y, Fukumoto H, Koh G, Yano H, Inagaki N, Yamada Y, Inoue K, Manabe T, Imura H: Over-expression of facilita- tive glucose transporter genes in human cancer. Biochem Biophys Res Commun 1990, 170:223-230
14. Grobholz R, Hacker HJ, Thorens B, Bannasch P: Reduction in the expression of glucose transporter protein GLUT 2 in preneoplastic and neoplastic hepatic lesions and reexpression of GLUT 1 in late stages of hepatocarcinogenesis. Cancer Res 1993, 53:4204-4211
15. Su TS, Tsai TF, Chi CW, Han SH, Chou CK: Elevation of facilitated glucose-transporter messenger RNA in human hepatocellular carcinoma. Hepatology 1990, 11:118-122
16. Younes M, Lechago LV, Somoano JR, Mosharaf M, Lechago J: Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers. Cancer Res 1996, 56:1164-1167
17. Zimmerman RL, Fogt F, Burke M, Murakata LA: Assessment of Glut-1 expression in cholangiocarcinoma, benign biliary lesions and hepa- tocellular carcinoma. Oncol Rep 2002, 9:689-692
18. Zimmerman RL, Burke M, Young NA, Solomides CC, Bibbo M: Diagnostic utility of Glut-1 and CA 15-3 in discriminating adenocarcinoma from hepatocellular carcinoma in liver tumors biopsied by fine-needle aspiration. Cancer 2002, 96:53-57
19. Roh MS, Jeong JS, Kim YH, Kim MC, Hong SH: Diagnostic utility of GLUT1 in the differential diagnosis of liver carcinomas. Hepatogas- troenterology 2004, 51:1315-1318
20. Hellerbrand C, Amann T, Schlegel J, Wild P, Bataille F, Spruss T, Hartmann A, Bosserhoff AK: The novel gene MIA2 acts as a tumour suppressor in hepatocellular carcinoma. Gut 2008, 57:243-251
21. Weiss TS, Jahn B, Cetto M, Jauch KW, Thasler WE: Collagen sandwich culture affects intracellular polyamine levels of human hepato-cytes. Cell Prolif 2002, 35:257-267
22. Chun YS, Yeo EJ, Choi E, Teng CM, Bae JM, Kim MS, Park JW: Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells. Biochem Pharmacol 2001, 61:947-954
23. Yeo EJ, Chun YS, Cho YS, Kim J, Lee JC, Kim MS, Park JW: YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 2003, 95:516-525
24. Kong D, Park EJ, Stephen AG, Calvani M, Cardellina JH, Monks A, Fisher RJ, Shoemaker RH, Melillo G: Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res 2005, 65:9047-9055
25. Hellerbrand C, Muhlbauer M, Wallner S, Schuierer M, Behrmann I, Bataille F, Weiss T, Scholmerich J, Bosserhoff AK: Promoter-hyper- methylation is causing functional relevant downregulation of methyl- thioadenosine phosphorylase (MTAP) expression in hepatocellular carcinoma. Carcinogenesis 2006, 27:64-72
26. Hellerbrand C, Bataille F, Schlegel J, Hartmann A, Muhlbauer M, Scholmerich J, Buttner R, Hofstadter F, Bosserhoff AK: In situ expression patterns of melanoma inhibitory activity 2 in healthy and diseased livers. Liver Int 2005, 25:357-366
27. Schuierer MM, Bataille F, Weiss TS, Hellerbrand C, Bosserhoff AK: Raf kinase inhibitor protein is downregulated in hepatocellular carcinoma. Oncol Rep 2006, 16:451-456
28. Bruckner BA, Ammini CV, Otal MP, Raizada MK, Stacpoole PW: Regulation of brain glucose transporters by glucose and oxygen deprivation. Metabolism 1999, 48:422-431
29. Dudas J, Mansuroglu T, Moriconi F, Haller F, Wilting J, Lorf T, Fuzesi L, Ramadori G: Altered regulation of Prox1-gene-expression in liver tumors. BMC Cancer 2008, 8:92
30. Levitsky LL, Zheng Q, Mink K, Rhoads DB: GLUT-1 and GLUT-2 mRNA, protein, and glucose transporter activity in cultured fetal and adult hepatocytes. Am J Physiol 1994, 267:E88-E94
31. Zheng Q, Levitsky LL, Mink K, Rhoads DB: Glucose regulation of glucose transporters in cultured adult and fetal hepatocytes. Metabolism 1995, 44:1553-1558
32. Tanaka H, Yamamoto M, Hashimoto N, Miyakoshi M, Tamakawa S, Yoshie M, Tokusashi Y, Yokoyama K, Yaginuma Y, Ogawa K: Hy- poxia-independent overexpression of hypoxia-inducible factor 1al- phaas an early change in mouse hepatocarcinogenesis. Cancer Res 2006, 66:11263-11270
33. Huang GW, Yang LY, Lu WQ: Expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in hepatocellular carcinoma: impact on neovascularization and survival. World J Gastroenterol 2005, 11:1705-1708
34. Yang ZF, Poon RT, To J, Ho DW, Fan ST: The potential role of hypoxia inducible factor 1alpha in tumor progression after hypoxia and chemotherapy in hepatocellular carcinoma. Cancer Res 2004, 64:5496-5503
35. Gwak GY, Yoon JH, Kim KM, Lee HS, Chung JW, Gores GJ: Hypoxia stimulates proliferation of human hepatoma cells through the induction of hexokinase II expression. J Hepatol 2005, 42:358-364
36. Pelicano H, Martin DS, Xu RH, Huang P: Glycolysis inhibition for anticancer treatment. Oncogene 2006, 25:4633-4646
37. Salas-Burgos A, Iserovich P, Zuniga F, Vera JC, Fischbarg J: Predicting the three-dimensional structure of the human facilitative glucose transporter glut1 by a novel evolutionary homology strategy: insights on the molecular mechanism of substrate migration, and binding sites for glucose and inhibitory molecules. Biophys J 2004, 87:2990-2999
38. Evans A, Bates V, Troy H, Hewitt S, Holbeck S, Chung YL, Phillips R, Stubbs M, Griffiths J, Airley R: Glut-1 as a therapeutic target: increased chemoresistance and HIF-1-independent link with cell turnover is revealed through COMPARE analysis and metabolomic studies. Cancer Chemother Pharmacol 2008, 61:377-393